PARASOL-FSGS
Proteinuria and Other Biomarkers as Endpoints for Clinical Trials in Kidney Disease
PARASOL AT ASN KIDNEY WEEK: OCTOBER 25-26, 2024
We held a translational session "Advancing the Understanding of Proteinuria and eGFR as FSGS Clinical Trial End Points" at ASN Kidney Week on Friday, October 25 as well as an
Informational Poster: Proteinuria and GFR as Clinical Trial Endpoints in FSGS (PARASOL)
Poster #: INFO10-SA
Session recordings are available at the ASN elearning center for registered meeting attendees.
PUBLIC SCIENTIFIC WORKSHOP: OCTOBER 7–8, 2024
The PARASOL workgroup presented key findings on proteinuria and GFR as clinical trial endpoints for FSGS at a public scientific workshop co-sponsored by the FDA, ISGD, NephCure, KHI, and NKF.BACKGROUND
FSGS is a rare kidney disease that affects patients of all ages and has a high risk of progression to kidney failure. There are no FDA-approved therapies for this disease. Thus, there is an urgent need to conduct randomized clinical trials and to develop safe and effective therapies for FSGS. While the FDA currently accepts a complete remission or near normalization of proteinuria as a surrogate endpoint and basis for traditional approval of new treatments for FSGS, further work is needed to support the use of lesser changes in proteinuria as a basis for accelerated or traditional approval.
The PARASOL project builds upon and continues the important foundational work in this area conducted since 2019 by the Kidney Health Initiative (KHI).
OBJECTIVES
The PARASOL group will achieve this in 2024 by conducting a large-scale analysis of existing data from patients of all ages with FSGS who are participants in observational cohort studies, regional or national registries, or real-world data sets. The project is sponsored by NephCure, the International Society of Glomerular Disease, the Kidney Health Initiative, and the National Kidney Foundation. The data analysis is led by a team from the Michigan Kidney Translational Medicine Center at the University of Michigan.
NEWS (FSGS)
- Read the summary of our October 7–8 Scientific Workshop where the PARASOL team presented the results of their analysis.
- The PARASOL results were also presented at ASN Kidney Week on October 25, 2024.
- Read an update from our interim meeting in Kidney News (August 2024). Download the poster and slides here.
- The organizing team held webinars on March 13-14 to introduce the project, provide progress updates, and answer questions. The content is especially geared toward industry, but accessible to all. Access the replay or download slides here.
- Watch our video about the goals of PARASOL:
- Read about PARASOL in the February 2024 issue of ASN's Kidney News: Community Collaborates to Address Clinical Trial Endpoints for FSGS
ORGANIZING COMMITTEE
- Matthias Kretzler, MD, University of Michigan (Co-Chair)
- Laura Mariani, MD, MSCE, FASN, University of Michigan (Co-Chair)
- Laurel Damashek, MA, International Society of Glomerular Disease
- Lauren Eva, NephCure
- Barbara Gillespie, MD, Fortrea; Adjunct Professor, UNC
- Tobias B. Huber, MD, International Society of Glomerular Disease and University Medical Center Hamburg-Eppendorf
- Alex Mercer, PhD, JAMCO Pharma Consulting
- Abigail Smith, PhD, Northwestern University
- Josh Tarnoff, NephCure
- Aliza Thompson, MD, MS, FDA
- Howard Trachtman, MD, University of Michigan
- Hailey Desmond, MS, University of Michigan
- Melissa West, American Society of Nephrology (Kidney Health Initiative)
- Kerry Willis, PhD, National Kidney Foundation
CONTACT THE PROJECT TEAM
Please contact the PARASOL team at parasol@is-gd.org if you have any questions about the project, are interested in contributing data, or would like to participate in another way.
SPONSORS
.png?width=300&name=NKF%20clear%20background%20(2000%20x%20500%20px).png)
